10-Q · May 14, 2026
XBiotech reported a net loss of $5.5 million for Q1 2026, a decrease from the $10.9 million loss in Q1 2025, reflecting improved cost management. The company continues to have no product revenue, forecasting significant…
Earnings analysis · 10-Q
XBIT earnings analysis
Filed August 13, 2026 · Our reading of the company's report
The latest report
The provided excerpt does not contain the June 30, 2026 income statement, balance sheet, cash-flow statement, segment disclosures, or MD&A, so revenue, margins, EPS, cash flow, liquidity, and operating trends cannot be…
Read full summary
The provided excerpt does not contain the June 30, 2026 income statement, balance sheet, cash-flow statement, segment disclosures, or MD&A, so revenue, margins, EPS, cash flow, liquidity, and operating trends cannot be quantified reliably. Management reported effective disclosure and financial-reporting controls as of June 30, 2026, with no material control changes during the quarter. The company also reported no material changes to the risk factors included in the December 31, 2025 Form 10-K.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Disclosure controls remain effective
Management concluded that disclosure controls and procedures were effective as of June 30, 2026, under Exchange Act Rules 13a-15(e) and 15d-15(e).
-
Financial reporting controls effective
Management concluded that internal control over financial reporting was effective as of June 30, 2026, providing reasonable assurance regarding reliable financial reporting under GAAP.
-
No material control changes
The company reported no change during the quarter ended June 30, 2026 that materially affected, or was reasonably likely to materially affect, internal control over financial reporting.
What to watch
-
Risk framework remains unchanged
The company reported no material changes to the risk factors in its Annual Report on Form 10-K for the year ended December 31, 2025. The filing nevertheless states that the disclosed risks could materially and adversely affect the business, financial condition, results of operations, and common-stock trading price.
Management's outlook
The provided filing excerpt contains no quantitative revenue or EPS outlook. The excerpt does not include the MD&A or the financial statements needed to assess current-period guidance.
Earlier filings 4
10-K · April 29, 2026
XBiotech remains focused on developing its True Human™ monoclonal antibodies, with a strategic emphasis on areas such as oncology and rheumatology. Despite ongoing R&D efforts, the company has not yet generated product…
10-K · March 13, 2026
XBiotech positions itself as a fully integrated developer of True Human™ monoclonal antibodies with a strategic focus on anti‑IL‑1α programs (oncology, rheumatology, neurology) and an infectious disease pipeline. The…
10-K · March 18, 2025
XBiotech is a clinical-stage biopharma focused on True Human™ monoclonal antibodies (notably anti‑IL‑1α programs). The company reports a promising signal from a 60‑subject pancreatic cancer (Natrunix) study (preliminary…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.